BioPharma Resources

Drug Trial Radar · NCT07427797

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 309 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

309

Actual

Start

Feb 27, 2026

Primary completion

Aug 12, 2026

Study completion Jul 14, 2027

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Feb 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effectiveness and safety of Corabotase (also known as IPN10200) compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence. In this study, all participants will receive a single injection of either Corabotase or placebo (the study drug). There will be 3 periods in this study: * A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre. * A treatment period (Day 1) where all the eligible participants will receive a single injection of IPN10200 or placebo. * A follow-up period (52 weeks) where participants' health will be monitored, consisting of regular visits to the study centre and 1 telephone call visit. Participants will undergo health measurements and observation, including blood sampling, physical examinations, clinical evaluations and electrocardiograms (ECG: recording of the electrical activity of heart). They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 55 weeks. Participants may withdraw consent to participate at any time.

Conditions

  • Moderate to Severe Glabellar Lines

Interventions

  • CorabotaseBiological

    A single vial of lyophilised powder for solution for injection will be injected locally into several sites across the glabellar region.

  • PlaceboBiological

    A single vial of lyophilised powder for solution, containing excipients without active substance, will be injected locally into several sites across the glabellar region.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For North America: Percentage of participants responding to treatmentTime frame: From baseline to week 4
  2. For EU and ROW: Percentage of participants responding to treatmentTime frame: From baseline to week 4

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Skin Wellness Dermatology - Homewood

    Birmingham, Alabama

  • Advanced Research Associates

    Glendale, Arizona

  • Avacare

    Scottsdale, Arizona

  • Investigate MD, LLC

    Scottsdale, Arizona

  • Ablon Skin Institute and Research Center

    Manhattan Beach, California

  • Keith A. Marcus, MD Inc

    Redondo Beach, California

  • West Dermatology

    San Diego, California

  • Ava T. Shamban, M.D., Inc.

    Santa Monica, California

  • Art of Skin MD

    Solana Beach, California

  • Pacific Clinical Innovations Inc.

    Vista, California

  • Skin Research Institute

    Coral Gables, Florida

  • ICON Dermatology and Aesthetics

    Bethesda, Maryland

  • Clinical Research Center of the Carolinas

    Charleston, South Carolina

  • Westlake Dermatology & Cosmetic Surgery - Westlake

    Austin, Texas

  • Dermatology and Laser Surgery Center

    Houston, Texas

  • Pflugerville Dermatology Clinical Research Center, Inc. d/b/a Austin Institute for Clinical Research

    Pflugerville, Texas

  • SkinDC

    Arlington, Virginia

  • Carruthers and Humphrey Cosmetic Medicine

    Vancouver, British Columbia, Canada

  • Pacific Dermaesthetics Inc.

    Vancouver, British Columbia, Canada

  • Institute of Cosmetic and Laser Surgery

    Oakville, Ontario, Canada

  • Sweat clinics of canada

    Toronto, Ontario, Canada

  • Bertucci MedSpa

    Woodbridge, Ontario, Canada

  • Centre de Recherche Dermatologique de Quebec

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.